30/06/2025
Accsys is on track in executing its Focus strategy, which it set out at its investor day in January 2025. Phase 1 of 3 is already yielding results, with a lean and mean organisation focused on accelerating volume growth and significantly improving adjusted EBITDA margins. The FY25 results were slightly better than we had expected, and the company had a good start to FY26. We have made small adjustments to our estimates but due to the roll-over of our discounted cash flow model by one year, the potential value per share is now €1.15 (up from €1.00).
24/06/2025
Accsys Technologies has reported its FY25 results (to 31 March), which are in line with its trading update of 7 May at the revenue and volume level but slightly exceed consensus at the adjusted EBITDA level. Including the volumes from the new plant in the US, total volumes were up a solid 13% y-o-y, with strong growth of 16% y-o-y in North America. Adjusted EBITDA strongly recovered from €4.8m in FY24 to €10.8m (consensus was €10.5m). The first phase of its Focus strategy is yielding results and Accsys is positive about FY26, expecting sales growth and margin progression after a positive start to the year.
03/06/2025
Accsys Technologies is a London- and Amsterdam-listed company with a market capitalisation of c £135m that manufactures premium, high-performance wood products under the Accoya and Tricoya brands. What sets Accsys apart is its unique acetylation process that creates sustainable wood products suited for demanding outdoor applications requiring durability and stability. We highlight the key points of Accsys’s investment story. Accsys has created a differentiated product in a traditional market. The company’s products’ performance advantages create compelling value despite premium pricing. Accsys’s addressable market opportunity is substantial and growing. New leadership is transforming the business with an operational focus. The company has set ambitious but achievable targets for 2030. If you would like to learn more about Accsys Technologies, please see our latest research.